← Back to Search

Exercise Intensity and Balance Training for Spinocerebellar Ataxia (PRIME-Ataxia Trial)

N/A
Waitlist Available
Led By Chelsea E Macpherson, DPT
Research Sponsored by Teachers College, Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Scale for Ataxia Rating and Assessment (SARA) score between 8-25/40, capturing mild-moderate disease
Able to walk with/without assistive device
Must not have
Cardiac/pulmonary conditions that would affect participants ability to participate exercise program
Severe visual complications associated with ataxia (i.e., Spontaneous nystagmus, retinal or optic nerve involvement, especially in SCA7) defined as have a score on the Snellen Visual Acuity test = 20/200 - 20/400, OR a visual field of 20 degrees of less.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, post-intervention (4 months)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing two different online exercise routines for people with spinocerebellar ataxias (SCAs). One routine involves intense cardio workouts before balance exercises, while the other involves light exercises like stretching before balance exercises. The goal is to see which routine better improves balance and motor skills in people with SCAs.

Who is the study for?
This trial is for people aged 18-85 with a confirmed genetic diagnosis of Spinocerebellar Ataxia types SCA1, 2, 3, 6, or 7. Participants should have mild to moderate disease severity and be able to walk with or without help. They need a care partner available during sessions and must not have been doing intense exercise recently.
What is being tested?
The PRIME-Ataxia study tests if high-intensity aerobic exercise before balance training is more effective than low-intensity exercise for the same purpose in individuals with SCAs. This telehealth program runs for eight weeks and includes an assessment of motor skill learning.
What are the potential side effects?
While specific side effects are not listed, typical risks may include muscle soreness, fatigue from high-intensity workouts, increased risk of falls due to balance issues especially post-exercise when fatigued.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My ataxia is mild to moderate, with a SARA score between 8-25.
Select...
I can walk, with or without help from a device.
Select...
My condition is genetically confirmed as SCA1, 2, 3, 6, or 7.
Select...
I am between 18 and 85 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My heart or lung condition doesn't limit my ability to exercise.
Select...
I have severe vision problems due to my ataxia.
Select...
I experience severe movement issues like stiffness, shaking, or Parkinson's symptoms.
Select...
I do not have any injuries that would stop me from exercising.
Select...
I do not have any diseases affecting my cerebellum like stroke or MS.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, post-intervention (4 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, post-intervention (4 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Cerebellar Cognitive Affective Syndrome Scale
Change in Patient Reported Outcome Measure for Ataxia
Change in Scale for Assessment and Rating for Ataxia
Secondary study objectives
Acceptability Questionnaire
Activities Specific Balance Scale (ABC)
Digital Biomarker of Dynamic Posturography
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group 1Experimental Treatment1 Intervention
High-Intensity Aerobic Exercise Prior to Balance Training
Group II: Group 2Active Control1 Intervention
Low-Intensity Exercise Prior to Balance Training

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Spinocerebellar Ataxias (SCAs) include physical therapy, occupational therapy, and aerobic exercise. High-intensity aerobic exercise, in particular, enhances cardiovascular fitness, which is crucial for overall health and stamina. This type of exercise also potentially improves motor function and balance by promoting neuroplasticity and strengthening the neuromuscular system. For SCA patients, these improvements can lead to better coordination, reduced ataxia symptoms, and an enhanced quality of life, making it a valuable component of their treatment regimen.
Endurance exercise training in a patient with central core disease.Therapeutic effectiveness of a single exercise session combined with WalkAide functional electrical stimulation in post-stroke patients: a crossover design study.A randomized controlled pilot trial of game-based training in individuals with spinocerebellar ataxia type 3.

Find a Location

Who is running the clinical trial?

Teachers College, Columbia UniversityLead Sponsor
26 Previous Clinical Trials
6,053 Total Patients Enrolled
Chelsea E Macpherson, DPTPrincipal InvestigatorTeachers College, Columbia University
Lori Quinn, PT, EdDPrincipal InvestigatorTeachers College, Columbia University

Media Library

High-Intensity Aerobic Exercise Prior to Balance Training Clinical Trial Eligibility Overview. Trial Name: NCT05826171 — N/A
Spinocerebellar Ataxias Research Study Groups: Group 1, Group 2
Spinocerebellar Ataxias Clinical Trial 2023: High-Intensity Aerobic Exercise Prior to Balance Training Highlights & Side Effects. Trial Name: NCT05826171 — N/A
High-Intensity Aerobic Exercise Prior to Balance Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT05826171 — N/A
~7 spots leftby Dec 2025